| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acarbose Monotherapy and Type 2 Diabetes Prevention in Eastern and Western Prediabetes: An Ethnicity-specific Meta-analysis
|
Hu, Ruijie
|
|
2015
|
37 |
8 |
p. 1798-1812
15 p.
|
artikel
|
| 2 |
Accelerating Regulatory Science Initiatives for the Development of Drugs for Alzheimer’s Disease in Japan
|
Moritoyo, Takashi
|
|
2015
|
37 |
8 |
p. 1622-1626
5 p.
|
artikel
|
| 3 |
Access to Clinical Therapeutics
|
Shader, Richard I.
|
|
2015
|
37 |
8 |
p. 1601-1603
3 p.
|
artikel
|
| 4 |
Corrigendum to ‘Effects of Rivaroxaban versus Warfarin on Hospitalization Days and other Health Care Resource Utilization in Patients with Nonvalvular Atrial Fibrillation: an Observational Study from a Cohort of Matched Users’
|
Laliberté, François
|
|
2015
|
37 |
8 |
p. 1870-1871
2 p.
|
artikel
|
| 5 |
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea
|
Lee, Min-Young
|
|
2015
|
37 |
8 |
p. 1662-1676.e2
165939 p.
|
artikel
|
| 6 |
Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States
|
Le, T. Kim
|
|
2015
|
37 |
8 |
p. 1713-1725.e3
1.723288E6 p.
|
artikel
|
| 7 |
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
|
Ehret, Megan J.
|
|
2015
|
37 |
8 |
p. 1604-1616
13 p.
|
artikel
|
| 8 |
Development of Novel Pharmaceutical Agents for Alzheimer’s Disease: The Impact of Regulatory Initiatives in Japan and the United States
|
Tsukamoto, Katsura
|
|
2015
|
37 |
8 |
p. 1652-1660
9 p.
|
artikel
|
| 9 |
Editorial Board
|
|
|
2015
|
37 |
8 |
p. A2-
1 p.
|
artikel
|
| 10 |
Effect of Atorvastatin on Serum Levels of Total Cholesterol and High-Sensitivity C-reactive Protein in High-Risk Patients with Atrial Fibrillation in Asia
|
Shi, Ming Yu
|
|
2015
|
37 |
8 |
p. 1740-1750
11 p.
|
artikel
|
| 11 |
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
|
Kovacs, Christopher S.
|
|
2015
|
37 |
8 |
p. 1773-1788.e1
16108 p.
|
artikel
|
| 12 |
Erratum to “The impact of reducing dose frequency on health outcomes”
|
|
|
2015
|
37 |
8 |
p. 1870-
1 p.
|
artikel
|
| 13 |
Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada
|
Skovgaard, Rasmus
|
|
2015
|
37 |
8 |
p. 1677-1688
12 p.
|
artikel
|
| 14 |
Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial
|
Na, Sang-Hoon
|
|
2015
|
37 |
8 |
p. 1726-1739
14 p.
|
artikel
|
| 15 |
Extemporaneous Formulations of Metformin for Pediatric Endocrinology: Physicochemical Integrity, Cytotoxicity of Sweeteners, and Quantitation of Plasma Levels
|
Alemón-Medina, Radamés
|
|
2015
|
37 |
8 |
p. 1689-1702
14 p.
|
artikel
|
| 16 |
Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success
|
Sugino, Haruhiko
|
|
2015
|
37 |
8 |
p. 1632-1642
11 p.
|
artikel
|
| 17 |
Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry
|
Milne, Christopher-Paul
|
|
2015
|
37 |
8 |
p. 1852-1858
7 p.
|
artikel
|
| 18 |
IncobotulinumtoxinA for Migraine: A Retrospective Case Series
|
Kazerooni, Rashid
|
|
2015
|
37 |
8 |
p. 1860-1864
5 p.
|
artikel
|
| 19 |
Patterns of Innovation in Alzheimer’s Disease Drug Development: A Strategic Assessment Based on Technological Maturity
|
Beierlein, Jennifer M.
|
|
2015
|
37 |
8 |
p. 1643-1651.e3
1.649358E6 p.
|
artikel
|
| 20 |
Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects
|
Macha, Sreeraj
|
|
2015
|
37 |
8 |
p. 1789-1796
8 p.
|
artikel
|
| 21 |
Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects
|
Song, Yan
|
|
2015
|
37 |
8 |
p. 1703-1712
10 p.
|
artikel
|
| 22 |
Response to letter received from Moore and Schug: Thakur et al. Impact of Prolonged-Release Oxycodone/Naloxone on Outcomes Affecting Patients׳ Daily Functioning in Comparison With Extended-Release Tapentadol: A Systematic Review
|
Thakur, Deepika
|
|
2015
|
37 |
8 |
p. 1867-1868
2 p.
|
artikel
|
| 23 |
Re: Thakur et al. Impact of Prolonged-Release Oxycodone/Naloxone on Outcomes Affecting Patients׳ Daily Functioning in Comparison With Extended-Release Tapentadol: A Systematic Review
|
Moore, Andrew
|
|
2015
|
37 |
8 |
p. 1866-1867
2 p.
|
artikel
|
| 24 |
Safety and Efficacy of a Needle-free Powder Lidocaine Delivery System in Pediatric Patients Undergoing Venipuncture or Peripheral Venous Cannulation: Randomized Double-blind COMFORT-004 Trial
|
Schmitz, Michael L.
|
|
2015
|
37 |
8 |
p. 1761-1772
12 p.
|
artikel
|
| 25 |
Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration
|
Lu, Meng-Yao
|
|
2015
|
37 |
8 |
p. 1751-1760
10 p.
|
artikel
|
| 26 |
Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy
|
Iglay, Kristy
|
|
2015
|
37 |
8 |
p. 1813-1821.e1
16398 p.
|
artikel
|
| 27 |
Table of Contents
|
|
|
2015
|
37 |
8 |
p. A4-A6
nvt p.
|
artikel
|
| 28 |
The Pathophysiology and Treatment of Osteoporosis
|
Drake, Matthew T.
|
|
2015
|
37 |
8 |
p. 1837-1850
14 p.
|
artikel
|
| 29 |
The Quest to Develop New Medicines to Treat Alzheimer’s Disease: Present Trends and Future Prospects
|
Kaitin, Kenneth I
|
|
2015
|
37 |
8 |
p. 1618-1621
4 p.
|
artikel
|
| 30 |
Understanding the Complexities of Cirrhosis
|
Muir, Andrew J.
|
|
2015
|
37 |
8 |
p. 1822-1836
15 p.
|
artikel
|
| 31 |
Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan ⁎ ⁎ The views expressed in this article are those of the author and do not necessarily reflect the official views of Ministry of Health, Labor, and Welfare, or the Pharmaceuticals Medical Devices Agency of Japan.
|
Otsubo, Yasuto
|
|
2015
|
37 |
8 |
p. 1627-1631
5 p.
|
artikel
|
Tijdschrift beschrijving